Mar. 30 at 11:20 PM
$NMRA longer term view remains largely unchanged, Neumora’s price action closely mirrors Wave Life Sciences
$WVE that plummeted ~50% on March 26 after disappointing obesity data.
This suggests the market recently stripped the Obesity Premium out of mid-cap biotechs, hitting
$NMRA particularly hard because of its own 1-year delay for NMRA-215.
Pure-play psychiatry stocks like Axsome (
$AXSM) and Intra-Cellular (
$ITCI) have remained remarkably stable. This is evidence that
$NMRA’s drop is not a rejection of its depression drug (Navacaprant), but rather a specific reaction to the obesity setback.
Historically when a stock drops 30%+ on a secondary asset delay (Obesity) while the primary asset (Depression) stays on track, it leads to a reversion once the panic selling subsides.
Long term view much higher with buyout potential probably pushed to 2027
https://www.marketbeat.com/instant-alerts/neumora-therapeutics-sees-unusually-large-options-volume-nasdaqnmra-2026-03-30/#google_vignette
